WASHINGTON, D.C. (April 7, 2022) – PhRMA spokesperson Nicole Longo issued the following statement:
“Sadly, CMS largely ignored concerns raised by patients, providers, manufacturers, policymakers and numerous other stakeholders and chose to finalize a policy that may effectively prevent doctors and patients from deciding whether a particular FDA-approved medicine is the right option for them. This decision sets the dangerous precedent of restricting Medicare Part B coverage and patient access for new and future FDA-approved medicines for patients with Alzheimer’s disease. CMS has further complicated matters by taking the unprecedented step of applying different standards for coverage of medicines depending on the FDA approval pathway taken, undermining the scientific assessment by experts at FDA. We hope the Administration reconsiders this policy immediately.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than $1 trillion in the search for new treatments and cures, including $91.1 billion in 2020 alone.
For information on how innovative medicines save lives, please visit:www.PhRMA.org